Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial
Palabras clave :
Cholinergic urticaria
Omalizumab
Clinical trial
Exercise
Exercise challenge test
Cholinergic urticaria
UCOL score
Fecha de publicación :
2019
Nota editorial :
© 2019 American Academy of Allergy, Asthma & Immunology
Cita:
Sabaté-Brescó, M. (Marina); Gastaminza, G. (Gabriel); Azofra, J. (Julián); et al. "Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial". The Journal of Allergy and Clinical Immunology: In Practice. 7 (5), 2019, 1599 - 1609
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.